NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene

Table 4 Association of the MAGEC1 P.Met1? variant with unselected PC or HPC

Sample group	Carrier frequency	OR (95% CI)	P
Male population controls	7/757 (0.92%)	1.00
Female population controls	5/764 (0.65%)	1.00
Patients with BPH	2/375 (0.53%)	1.00
PSA controls	9/746 (1.21%)	1.00
Patients with unselected PC	13/757 (1.72%)	1.99 (1.00-3.95)*	0.04*
		2.35 (1.10-5.02)**	0.02**
Patients with HPC	4/163 (2.45%)	2.86 (0.98-8.38)*	0.04*
		3.38 (1.10-10.40)**	0.02**

*Male and female blood donors, BPH patients, and PSA controls used as a control group.
**Male and female blood donors and BPH patients used as a control group.

ISSN: 1471-2407